# Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations

> **NCT06567860** · PHASE4 · COMPLETED · sponsor: **La Jolla Institute for Immunology** · enrollment: 23 (actual)

## Conditions studied

- Influenza A

## Interventions

- **BIOLOGICAL:** Influenza Fluzone vaccine

## Key facts

- **NCT ID:** NCT06567860
- **Lead sponsor:** La Jolla Institute for Immunology
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-21
- **Primary completion:** 2025-02-06
- **Final completion:** 2025-02-06
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2026-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06567860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06567860, "Characterizing Late-season Influenza Vaccine Responses to Compare the 2023 and 2024 Vaccine Formulations". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06567860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*